QIAGEN Announces Closing of the Acquisition of ...

VENLO, The  Netherlands, December  14, 2009  - QIAGEN  N.V.  (NASDAQ:
QGEN; Frankfurt, Prime Standard: QIA) today announced the  completion
of its previously announced acquisition of SABiosciences Corporation,
a  privately-held  developer   and  manufacturer   of  disease-   and
pathway-focused PCR assay panels based in Frederick, Maryland  (USA).
The closing follows the approval of the acquisition by SABiosciences'
stockholders and  the  expiration  of the  statutory  30-day  waiting
period under  the  Hart-Scott-Rodino Antitrust  Improvements  Act  of
1976. QIAGEN had  announced the  signing of a  definite agreement  to
acquire SABiosciences on November 9, 2009.

"We are pleased to now have completed the transaction", said Peer  M.
Schatz, Chief Executive  Officer of  QIAGEN. "Together  with our  new
colleagues we will initiate the integration process. We believe  this
process will be  a quick and  smooth one  - given the  high level  of
complementarities. I would  like to use  this opportunity to  welcome
our new employees to QIAGEN.  Their competence will help us  leverage
the combined Company's  value proposition in  the field of  biomarker
discovery and validation  for the development  of future  diagnostics
and pharmaceuticals."

SABiosciences brings to QIAGEN  a unique position  in the design  and
commercialization of more than 100  PCR assay panels which allow  for
high-performance  analysis  of  DNA,  RNA,  epigenetic  and  microRNA
targets in biological pathways  associated with specific diseases  or
with defined pathways. These assay  panels may be operated on  QIAGEN
instruments in the future. QIAGEN expects that the combined  offering
will  strengthen  its   position  as  a   premium  partner  for   the
pharmaceutical industry and to yield content for its three  molecular
diagnostic   segments:   prevention,   profiling   and   personalized
healthcare.

QIAGEN had already disclosed its intention to expand the business  of
disease-  and  pathway-focused  assay  panels  and  to  further  grow
SABiosciences' Frederick site as a Center of Excellence in biological
content  development.  The  proximity  to  QIAGEN's  North   American
headquarters in Maryland  is expected  to contribute to  a rapid  and
smooth integration.

Until further notice, customers in the U.S. can continue to order PCR
assay panels  from SABiosciences'  website at  www.sabiosciences.com,
while  customers based  outside the U.S. can  order from their  local
distributors.

In the November  9 announcement  of the acquisition,  QIAGEN said  it
expects the transaction:


  * To add revenues of approximately US$24 million in sales for 2010.
    The growth rate on these US$24 million in revenues is expected
    above QIAGEN's average growth rate.
  * To incur one-time charges of approximately US$0.02 in earnings
    per share (EPS) in the last quarter of 2009 which primarily
    relates to costs and expenses incurred in connection with the
    acquisition such as advisory fees as well as the write-off of
    certain assets.
  * To be neutral to EPS in 2010 on an adjusted basis excluding
    one-time charges, integration and restructuring costs, and
    amortization of acquisition related intangible assets, and to be
    significantly accretive to adjusted EPS in 2011.

The transaction was  valued at  approximately US$90  million in  cash
subject to customary purchase price adjustments.

About QIAGEN:
QIAGEN   N.V.,    a    Netherlands   holding    company,    is    the
leading global provider of  sample  and  assay  technologies.  Sample
technologies are used to  isolate and process  DNA, RNA and  proteins
from biological samples such  as blood or tissue. Assay  technologies
are used  to make  such isolated  bio-molecules visible.  QIAGEN  has
developed and markets more than 500 sample and assay products as well
as automated solutions for such consumables. The company provides its
products to molecular diagnostics laboratories, academic researchers,
pharmaceutical   and    biotechnology    companies,    and    applied
testing customers for  purposes such  as forensics,  animal  or  food
testing   and   pharmaceutical   process   control. QIAGEN's    assay
technologies  include  one  of  the  broadest  panels  of   molecular
diagnostic tests available worldwide. This panel includes the  digene
HPV Test,  which is  regarded as  a "gold  standard" in  testing  for
high-risk types of human papillomavirus  (HPV), the primary cause  of
cervical cancer, as well as a broad suite of solutions for infectious
disease testing and companion  diagnostics. QIAGEN employs more  than
3,400 people  in over  30  locations worldwide.  Further  information
about QIAGEN can be found at 

http://www.qiagen.com/.


SAFE HARBOR STATEMENT
Statements contained in  this release that  are not historical  facts
are  forward-looking  statements,  including  statements  about   our
products, markets, strategy  and operating  results. Such  statements
are  based   on  current   expectations   that  involve   risks   and
uncertainties including, but not  limited to, those associated  with:
management of growth and international operations (including currency
fluctuations and logistics),  variability of  our operating  results,
commercial development  of our  markets (including  applied  testing,
clinical  and  academic  research,  proteomics,  women's   health/HPV
testing, molecular diagnostics, personalized healthcare and companion
diagnostics),  our  relationships   with  customers,  suppliers   and
strategic partners, competition, changes in technology,  fluctuations
in  demand,  regulatory  requirements,  identifying,  developing  and
producing integrated  products differentiated  from our  competitors'
products, market  acceptance  of  our products,  and  integration  of
acquired technologies and businesses. For further information,  refer
to our  filings  with  the  SEC,  including  our  latest  Form  20-F.
Information in this release is as of the date of the release, and  we
undertake no duty to update this information unless required by law.
                                # # #


Contacts:


Investor Relations:                      Public Relations:
Dr. Solveigh Mähler                      Dr. Thomas Theuringer
Director Investor Relations              Associate  Director   Public
QIAGEN N.V.                              Relations
[phone]                        QIAGEN GmbH
e-mail: [e-mail]      [phone]
                                         e-mail:
Albert F. Fleury                         [e-mail]
Investor Relations North America
QIAGEN N.V.
[phone]
e-mail: [e-mail]


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.